The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase Ib, open-label, dose-finding study of ruxolitinib in patients (pts) with primary myelofibrosis (PMF), post-polycythemia vera-myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF) and baseline platelets (PLTs) 50 to <100 x 109/l.
Heinz Gisslinger
No relevant relationships to disclose
Mary Frances McMullin
Honoraria - Novartis
Nadja Jaekel
No relevant relationships to disclose
Carole Brennan Miller
Consultant or Advisory Role - Novartis
Honoraria - Novartis (I)
Research Funding - Novartis
Srdan Verstovsek
Honoraria - Novartis
Research Funding - Incyte; Incyte
Claire N Harrison
Consultant or Advisory Role - Celgene; Celgene; Novartis; Novartis; S*Bio; S*Bio; Sanofi ; Sanofi ; YM BioSciences; YM BioSciences
Honoraria - Celgene; Celgene; Novartis; Novartis; S*Bio; S*Bio; Sanofi ; Sanofi ; YM BioSciences; YM BioSciences
Research Funding - Novartis; Novartis
Expert Testimony - S*Bio; S*Bio
Giovanni Barosi
No relevant relationships to disclose
Jean-Jacques Kiladjian
Research Funding - Celgene; Novartis; Shire
Haifa-Kathrin Al-Ali
Honoraria - Novartis
Research Funding - Novartis
Denis Weber
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Jing Hu
Employment or Leadership Position - Novartis
L. Andres Sirulnik
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Alessandro M. Vannucchi
Consultant or Advisory Role - Italfarmaco; Novartis
Honoraria - Italfarmaco; Novartis